Focused on the treatment of acute and chronic pain
Location: United States, California, San Francisco
Employees: 51-200
Total raised: $16M
Founded date: 2007
Investors 1
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.01.2017 | Series B | $16M | - |
Mentions in press and media 6
| Date | Title | Description |
| 11.01.2017 | Term Sheet — Wednesday, January 11 | DOLLARS AND DEALS Everything besides this news and Donald Trump’s scheduled press conference seems beside the point this morning, so here’s some venture data and private equity macro predictions to distract you. (If the topic of Trump, his ... |
| 11.01.2017 | Adynxx Grabs $16M in Series B | SAN FRANCISCO, CA, developer of a first-in-class platform of therapeutics for the prevention and resolution of chronic pain, has raised $16 million in a Series B financing round. >> Click here for more funding data on Adynxx >&... |
| 10.01.2017 | Adynxx Closes $16M Series B Financing | Adynxx, a San Francisco, CA-based clinical-stage pharmaceutical company, raised $16m in Series B financing round. The round was led by new investor TPG Biotech, with participation from existing investor Domain Associates. In conjunction wit... |
| 25.02.2013 | Cubist Announces Exclusive Option To Acquire Adynxx | |
| 07.09.2012 | Clinical-stage Adynxx looks for success treating pain as a disease rather than a symptom | The company has two goals, according to founder and chief scientific officer Julien Mamet, who’s also the inventor of the technology: First is to prevent pain after surgery, and second is to treat pain in chronic conditions. In its first ap... |
| - | Clinical-stage Adynxx looks for success treating pain as a disease rather than a symptom | Despite the many avenues for treating pain these days, the Institute of Medicine estimates that it costs the U.S. a whopping $635 billion annually in medical charges and lost productivity. That’s the problem a young San Francisco pharmaceut... |